Abstract:ABSTRACT Bacteria exposed to bactericidal treatment, such as antibiotics or bacteriophages (phages), often develop resistance. While phage therapy is proposed as a solution to the antibiotic resistance crisis, the bacterial resistance emerging during phage therapy remains poorly characterized. In this study, we examined a large population of phage-resistant extra-intestinal pathogenic Escherichia coli 536 clones that emerged from both in vitro (non-limited liquid medium) and in vivo (murine pneumonia) conditions. Genome sequencing uncovered a convergent mutational pattern in phage resistance mechanisms under both conditions, particularly targeting two cell-wall components, the K15 capsule and the lipopolysaccharide (LPS). This suggests that their identification in vivo could be predicted from in vitro assays. Phage-resistant clones exhibited a wide range of fitness according to in vitro tests, growth rate, and resistance to amoeba grazing, which could not distinguish between the K15 capsule and LPS mutants. In contrast, K15 capsule mutants retained virulence comparable to the wild-type strain, whereas LPS mutants showed significant attenuation in the murine pneumonia model. Additionally, we observed that resistance to the therapeutic phage through a nonspecific mechanism, such as capsule overproduction, did not systematically lead to co-resistance to other phages that were initially capable or incapable of infecting the wild-type strain. Our findings highlight the importance of incorporating a diverse range of phages in the design of therapeutic cocktails to target potential future phage-resistant clones effectively. IMPORTANCE This study isolated more than 50 phage-resistant mutants from both in vitro and in vivo conditions, exposing an extra-intestinal pathogenic Escherichia coli strain to a single virulent phage. The characterization of these clones revealed several key findings: (1) mutations occurring during phage treatment affect the same pathways as those identified in vitro ; (2) the resistance mechanisms are associated with the modification of two cell-wall components, with one involving receptor deletion (phage-specific mechanism) and the other, less frequent, involving receptor masking (phage-nonspecific mechanism); (3) an in vivo virulence assay demonstrated that the absence of the receptor abolishes virulence while masking the receptor preserves it; and (4) clones with a resistance mechanism nonspecific to a particular phage can remain susceptible to other phages. This supports the idea of incorporating diverse phages into therapeutic cocktails designed to collectively target both wild-type and phage-resistant strains, including those with resistance mechanisms nonspecific to a phage.

Bacteriophage uptake by mammalian cell layers represents a potential sink that may impact phage therapy

Phage-Enabled Nanomedicine: from Probes to Therapeutics in Precision Medicine.

Evaluation of the impact of repeated intravenous phage doses on mammalian host–phage interactions

Local Bacteriophage Delivery for Treatment and Prevention of Bacterial Infections

Improving the Safety and Efficacy of Phage Therapy from the Perspective of Phage-Mammal Interactions.

Phage-specific immunity impairs efficacy of bacteriophage targeting Vancomycin Resistant Enterococcus in a murine model

Bacteriophage Isolation, Purification, and Characterization Techniques Against Ubiquitous Opportunistic Pathogens

Bacteriophage–Host Interactions and the Therapeutic Potential of Bacteriophages

Schlesinger Nailed It! Assessing a Key Primary Pharmacodynamic Property of Phages for Phage Therapy: Virion Encounter Rates with Motionless Bacterial Targets

The untapped potential of phage model systems as therapeutic agents

Biological foundations of successful bacteriophage therapy

Variable fitness effects of bacteriophage resistance mutations in Escherichia coli: implications for phage therapy

Bacteriophage defends murine gut from Escherichia coli invasion via mucosal adherence

Optimized Dosing and Delivery of Bacteriophage Therapy for Wound Infections

Biodistribution of Liposome-Encapsulated Bacteriophages and Their Transcytosis During Oral Phage Therapy

Phage administration with repeated intravenous doses leads to faster phage clearance in mammalian hosts

Using a human colonoid-derived monolayer to study bacteriophage translocation

The contribution of neutrophils to bacteriophage clearance and pharmacokinetics in vivo

Interactions of Bacteriophages with Animal and Human Organisms—Safety Issues in the Light of Phage Therapy

Relevance of the bacteriophage adherence to mucus model for Pseudomonas aeruginosa phages